Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ICPT's Cash to Debt is ranked higher than
78% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. ICPT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ICPT' s Cash to Debt Range Over the Past 10 Years
Min: 218.39  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.82
ICPT's Equity to Asset is ranked higher than
69% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ICPT: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
ICPT' s Equity to Asset Range Over the Past 10 Years
Min: -1.08  Med: 0.71 Max: 0.96
Current: 0.82
-1.08
0.96
Interest Coverage No Debt
ICPT's Interest Coverage is ranked higher than
67% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ICPT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ICPT' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: 18.95
M-Score: -5.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -17793.32
ICPT's Operating margin (%) is ranked lower than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. ICPT: -17793.32 )
Ranked among companies with meaningful Operating margin (%) only.
ICPT' s Operating margin (%) Range Over the Past 10 Years
Min: -8237.1  Med: -2432.31 Max: -766.2
Current: -17793.32
-8237.1
-766.2
Net-margin (%) -17614.71
ICPT's Net-margin (%) is ranked lower than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. ICPT: -17614.71 )
Ranked among companies with meaningful Net-margin (%) only.
ICPT' s Net-margin (%) Range Over the Past 10 Years
Min: -16258.67  Med: -4179.53 Max: -705.71
Current: -17614.71
-16258.67
-705.71
ROE (%) -54.33
ICPT's ROE (%) is ranked lower than
64% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. ICPT: -54.33 )
Ranked among companies with meaningful ROE (%) only.
ICPT' s ROE (%) Range Over the Past 10 Years
Min: -180.8  Med: -118.75 Max: -54.36
Current: -54.33
-180.8
-54.36
ROA (%) -49.93
ICPT's ROA (%) is ranked lower than
69% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ICPT: -49.93 )
Ranked among companies with meaningful ROA (%) only.
ICPT' s ROA (%) Range Over the Past 10 Years
Min: -140.05  Med: -66.30 Max: -49.77
Current: -49.93
-140.05
-49.77
ROC (Joel Greenblatt) (%) -3237.76
ICPT's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ICPT: -3237.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICPT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8893.89  Med: -4333.00 Max: -2882.65
Current: -3237.76
-8893.89
-2882.65
Revenue Growth (3Y)(%) -33.00
ICPT's Revenue Growth (3Y)(%) is ranked lower than
79% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ICPT: -33.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ICPT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.00 Max: -20.6
Current: -33
EBITDA Growth (3Y)(%) 47.70
ICPT's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ICPT: 47.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ICPT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: 47.70 Max: 63.1
Current: 47.7
-22.9
63.1
EPS Growth (3Y)(%) 9.10
ICPT's EPS Growth (3Y)(%) is ranked higher than
68% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. ICPT: 9.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ICPT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.4  Med: 9.10 Max: 110.3
Current: 9.1
-11.4
110.3
» ICPT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ICPT Guru Trades in Q2 2015

Jim Simons 61,400 sh (New)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Columbia Wanger 275,679 sh (-12.72%)
» More
Q3 2015

ICPT Guru Trades in Q3 2015

Jim Simons 61,600 sh (+0.33%)
Columbia Wanger 209,818 sh (-23.89%)
» More
Q4 2015

ICPT Guru Trades in Q4 2015

George Soros 2,800 sh (New)
Jim Simons Sold Out
Columbia Wanger 186,872 sh (-10.94%)
» More
Q1 2016

ICPT Guru Trades in Q1 2016

Steven Cohen 10,300 sh (New)
Columbia Wanger 187,043 sh (+0.09%)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ACAD, OTCPK:BTGGF, NAS:TECH, OTCPK:LBTSF, NYSE:XON, NAS:JUNO, NAS:CBPO, NAS:IONS, OTCPK:SOLTF, NAS:ANAC, NAS:KITE, NAS:UTHR, NAS:ALNY, NAS:LGND, OTCPK:SBMFF, NAS:GLPG, NAS:TSRO, NAS:NKTR, OTCPK:ABCZY, NAS:RARE » details
Traded in other countries:I4P.Germany,
Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry.

Intercept Pharmaceuticals Inc was incorporated in the State of Delaware on September 4, 2002. It is a biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry. The Company's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. The Company's product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which it believes has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial that it anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. The Company currently expects results from the trial to be available by mid-2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC. The Company owns the rights to OCA outside of Japan and China, where it has exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Some of the competitors are Eli Lilly, Exelixis, Inc. and Phenex Pharmaceuticals AG. Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.

Ratios

vs
industry
vs
history
P/B 7.21
ICPT's P/B is ranked lower than
77% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. ICPT: 7.21 )
Ranked among companies with meaningful P/B only.
ICPT' s P/B Range Over the Past 10 Years
Min: 3.99  Med: 9.65 Max: 104.9
Current: 7.21
3.99
104.9
P/S 1931.35
ICPT's P/S is ranked lower than
98% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ICPT: 1931.35 )
Ranked among companies with meaningful P/S only.
ICPT' s P/S Range Over the Past 10 Years
Min: 42.02  Med: 1748.82 Max: 5193.93
Current: 1931.35
42.02
5193.93
EV-to-EBIT -9.34
ICPT's EV-to-EBIT is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. ICPT: -9.34 )
Ranked among companies with meaningful EV-to-EBIT only.
ICPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -200.1  Med: -25.70 Max: -3.6
Current: -9.34
-200.1
-3.6
EV-to-EBITDA -9.40
ICPT's EV-to-EBITDA is ranked lower than
99.99% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. ICPT: -9.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -200.6  Med: -25.80 Max: -3.7
Current: -9.4
-200.6
-3.7
Current Ratio 5.79
ICPT's Current Ratio is ranked higher than
58% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ICPT: 5.79 )
Ranked among companies with meaningful Current Ratio only.
ICPT' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 16.13 Max: 31.15
Current: 5.79
0.48
31.15
Quick Ratio 5.79
ICPT's Quick Ratio is ranked higher than
59% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. ICPT: 5.79 )
Ranked among companies with meaningful Quick Ratio only.
ICPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 16.13 Max: 31.15
Current: 5.79
0.48
31.15
Days Sales Outstanding 756.44
ICPT's Days Sales Outstanding is ranked lower than
99% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. ICPT: 756.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 80.13  Med: 306.54 Max: 535.77
Current: 756.44
80.13
535.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.78
ICPT's Price/Net Cash is ranked lower than
64% of the 691 Companies
in the Global Biotechnology industry.

( Industry Median: 4.99 vs. ICPT: 7.78 )
Ranked among companies with meaningful Price/Net Cash only.
ICPT' s Price/Net Cash Range Over the Past 10 Years
Min: 6.12  Med: 10.56 Max: 20.35
Current: 7.78
6.12
20.35
Price/Net Current Asset Value 7.48
ICPT's Price/Net Current Asset Value is ranked lower than
64% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. ICPT: 7.48 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICPT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 6.06  Med: 10.27 Max: 19.86
Current: 7.48
6.06
19.86
Price/Tangible Book 7.20
ICPT's Price/Tangible Book is ranked lower than
70% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. ICPT: 7.20 )
Ranked among companies with meaningful Price/Tangible Book only.
ICPT' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.94  Med: 10.22 Max: 19.33
Current: 7.2
5.94
19.33
Price/Median PS Value 1.10
ICPT's Price/Median PS Value is ranked lower than
63% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ICPT: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
ICPT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.88 Max: 2.12
Current: 1.1
0.03
2.12
Earnings Yield (Greenblatt) (%) -10.73
ICPT's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. ICPT: -10.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICPT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.01  Med: 0.00 Max: 0
Current: -10.73
-13.01
0

More Statistics

Revenue (TTM) (Mil) $1.78
EPS (TTM) $ -12.93
Beta-2.44
Short Percentage of Float39.66%
52-Week Range $89.76 - 285.00
Shares Outstanding (Mil)24.60

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22 117 386
EPS ($) -16.07 -14.57 -6.28
EPS w/o NRI ($) -16.07 -14.57 -6.28
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Intercept Pharmaceuticals Inc (ICPT) Moves Forward With OCA REGENERATE Trial; Buy Why Did Shares Sli May 20 2015 
Analysts are Positive on Intercept Pharmaceuticals Inc Following Quarterly Earnings and Pipeline Upd May 12 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST Mar 30 2015 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc, Ross Stores Inc, Sally Beauty Holdings In Mar 30 2015 
Intercept Pharmaceuticals Announces Two New Sub-Groups for FLINT Trial Mar 24 2015 
Intercept Pharma’s Losses Widen, but Revenue Rises Mar 03 2015 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Intercept Pharmaceuticals (ICPT) Obeticholic Acid Momentum, Gigamon (GIMO) Robust Revenue Growth Jan 30 2015 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 

More From Other Websites
Intercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : June 17, 2016 Jun 17 2016
Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US :... Jun 14 2016
How Are XBI’s Holdings’ Moving Averages Trending? Jun 13 2016
INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 10 2016
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer Jun 09 2016
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer Jun 09 2016
Intercept to Present at Upcoming Investor Conferences Jun 01 2016
Intercept to Present at Upcoming Investor Conferences Jun 01 2016
Intercept: Can Ocaliva's Approval Attract Gilead? Jun 01 2016
Here's Why Intercept Pharma (ICPT) Stock Is Gaining Today May 31 2016
Intercept Pharma’s new liver disease drug comes with hefty price tag: $70,000 a year May 31 2016
Intercept Pharma's chronic liver disease drug gets accelerated FDA approval May 31 2016
INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... May 31 2016
Trending Now: ICPT May 30 2016
Intercept's (ICPT) Liver Dug Ocaliva Approved by the FDA May 30 2016
Intercept Wins FDA Approval for Drug to Treat Liver Disease May 28 2016
FDA Grants Accelerated Approval to Ocaliva™ (Obeticholic Acid) for the Treatment of Patients with... May 27 2016
FDA Grants Accelerated Approval to Ocaliva™ (Obeticholic Acid) for the Treatment of Patients with... May 27 2016
Investors Eager for Gilead to Make Big Moves May 26 2016
INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 25 2016
Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US :... May 25 2016
Adaptimmune Strengthens Board with Appointment of Barbara Duncan May 24 2016
2 Hotly Debated Drugs Due For FDA Decisions This Week May 23 2016
INTERCEPT PHARMACEUTICALS INC Financials May 18 2016
Intercept Announces Ocaliva™ (Obeticholic Acid) Data in PBC to be Presented at DDW 2016 May 18 2016
Intercept Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update May 05 2016
Intercept to Report First Quarter 2016 Financial Results on May 5 Apr 28 2016
Intercept Announces Winners of Practice to Policy Health Awards Program to Encourage New Research... Apr 16 2016
FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva™ (obeticholic acid)... Apr 07 2016
Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016 Mar 30 2016
Intercept reports 4Q loss Feb 23 2016
Exclusive: Intercept Pharmaceuticals explores potential sale - sources Feb 12 2016
FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC Dec 17 2015
Gino Santini and Daniel Welch Elected to Board of Directors of Intercept Pharmaceuticals Dec 11 2015
Intercept Pharmaceuticals Announces Initiation of Prospective Trial to Explore Effect of Combined... Dec 07 2015
Intercept to Present at the Oppenheimer Healthcare Conference Dec 02 2015
Intercept Pharmaceuticals Initiates Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist Nov 30 2015
Intercept Presents New PBC Data at AASLD 2015 Nov 30 2015
Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic... Nov 14 2015
Intercept reports 3Q loss Nov 09 2015
Intercept Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Business Update Nov 09 2015
Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting Nov 03 2015
Intercept to Report Third Quarter 2015 Financial Results on November 9th Nov 02 2015
Intercept Pharmaceuticals Announces Results of Phase 2 Trial of OCA in NASH Patients in Japan Oct 28 2015
Intercept reports 2Q loss Aug 05 2015
Intercept reports 1Q loss May 11 2015
Intercept misses 4Q profit forecasts Mar 02 2015
Intercept misses 3Q profit forecasts Nov 07 2014
Ahead of the Bell: Intercept Pharma shares soar Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)